Bradyzide di(trifluoroacetate) salt hydrate, >=98%
Biochem/physiol Actions
Potent, orally active, non-peptide B2 bradykinin receptor antagonist.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5 mg in glass bottle
25 mg in poly bottle
| Quality Level | 100 |
|---|---|
| Manufacturer | SIGMA-ALDRICH |
| Storage Temp. | −20°C |
| Solubility | H2O: >40 mg/mL |
| Form | solid |
| Assay | ≥98% |
There are no downloads for this product.
